The previous FAST-TRAC award to Dr. Weeber identified minocycline as a potential therapeutic for Angelman Syndrome; reversing deficits of learning, memory, and motor skills in the AS mouse model.  This award provide additional funds to repeat these studies and increase the number of mice analyzed and add additional testing methods for testing the efficacy of minocycline in this model.  These studies will form the basis of the application for IRB approval for a potential clinical trial of minocycline in patients with AS.